Results 41 to 50 of about 424,109 (164)

mRNA-1273 [PDF]

Reactions Weekly, 2022
  +9 more sources

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Microbiology Spectrum, 2021
Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg ...
José G. Montoya, Amy E. Adams, Valérie Bonetti, Sien Deng, Nan A. Link, Suzanne Pertsch, Kjerstie Olson, Martina Li, Ellis C. Dillon, Dominick L. Frosch   +9 more
doaj   +1 more source

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera. [PDF]

Front Immunol
IntroductionThe first vaccines approved against SARS-CoV-2, mRNA-1273 and BNT162b2, utilized mRNA platforms. However, little is known about the proteomic markers and pathways associated with host immune responses to mRNA vaccination.
Hickey TE, Mudunuri U, Hempel HA, Kemp TJ, Roche NV, Talsania K, Sellers BA, Cherry JM, Pinto LA.   +8 more
europepmc   +3 more sources

mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients. [PDF]

Front Immunol
BackgroundCell-mediated immunity may provide durable protection against severe COVID-19, including among solid organ transplant recipients (SOTRs). This exploratory analysis in the open-label phase 3b trial evaluated cell-mediated immunity of mRNA-1273 ...
Girard B, Figueroa AL, De Rosa SC, McElrath MJ, Azzi JR, Stolman D, Siangphoe U, de Windt E, Miller JM, Das R, Priddy F.   +10 more
europepmc   +3 more sources

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

Vaccines, 2023
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines.
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Donchida Srimuan, Thaksaporn Thatsanathorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan   +16 more
doaj   +1 more source

Breakhthrough Infection Pasca Pemberian Booster mRNA Heterolog pada Tenaga Kesehatan di RSUD Arifin Achmad

Majalah Kedokteran Andalas, 2023
Tujuan: Mengetahui prevalensi dan karakteristik responden breakthrough infection pada tenaga kesehatan di RSUD Arifin Achmad Provinsi Riau dalam 14 hari – 6 bulan pasca vaksinasi booster mRNA-1273. Metode: Metode penelitian cross sectional yang dilakukan
Dina Br Nababan, Eka Bebasari, Ligat Pribadi Sembiring, Dani Rosdiana, Rahmat Azhari Kemal   +4 more
doaj   +1 more source

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age [PDF]

, 2022
BACKGROUND: The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. METHODS: Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was
Chronis, Carey, Ramirez Schrempp, Daniela, Creech, C. Buddy, Griffin, Carl, Smith, Christopher A., Girard, Bethany, Garner, Fredric, Ampajwala, Madhavi, Smith, Christopher A, Berman, Gary, Zervos, Marcus, Anderson, Evan J., Das, Rituparna, Slobod, Karen, Johnson, Kimball A., Tomassini, Joanne E, Johnson, Kimball A, Muller, William J, Aunins, Anne, Turner, Mark, Tomassini, Joanne E., Ali, Kashif, Gerber, Jeffrey, Fuchs, George, Kuter, Barbara, McPhee, Roderick, Bennett, Richard L., Zervos, Marcus J, Nayak, Jennifer, Miller, Jacqueline M., Piramzadian, Arin, Berthaud, Vladimir, Muller, William J., Creech, C Buddy, Reuter, Caroline, Zhao, Xiaoping, Bennett, Richard L, Anderson, Evan J, Palanpurwala, Khozema, Hautzinger, Kelly, Deng, Weiping, Zhou, Honghong, KidCOVE Study Group, Rizzardi, Barbara, Pajon, Rolando, Hsia, Daniel, DeLucia, Dianne, Schnyder Ghamloush, Sabine, Miller, Jacqueline M   +48 more
core   +2 more sources

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Human Vaccines & Immunotherapeutics, 2023
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still ...
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R. Lowy, Ligia A. Pinto   +8 more
doaj   +1 more source

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

International Journal of Infectious Diseases, 2023
Intro: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration.
A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari   +5 more
doaj   +1 more source

DataSheet_1_Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection.docx [PDF]

, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Jeffrey M. Wilson (3036432), Will H. Eschenbacher (12267677), Barbara J. Mann (270746), Michael R. Nelson (12267683), Thomas A.E. Platts-Mills (5425607), Nathan E. Richards (12267668), Emily C. McGowan (12267680), Lyndsey M. Muehling (12267671), Jaimin Patel (3257574), Behnam Keshavarz (12267665), Savannah G. Brovero (10702084), Deborah D. Murphy (4050487), Judith A. Woodfolk (4050496), Alexandra Kadl (12267686), Lisa J. Workman (11939969), Glenda Canderan (244202), Samuel M. Ailsworth (12267674)   +16 more
core   +1 more source